Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01527916 | Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease | PHASE2 | COMPLETED | 438 | — | — | Feb 1, 2012 | Nov 1, 2013 | Nov 19, 2014 | 33 | United States, Poland +4 |
| Arm | Type | Description |
|---|---|---|
| sugar pill | PLACEBO_COMPARATOR | - |
| donepezil | ACTIVE_COMPARATOR | - |
| ABT-126 Low Dose | EXPERIMENTAL | low dose |
| ABT-126 Middle Dose | EXPERIMENTAL | middle dose |
| ABT-126 high dose | EXPERIMENTAL | high dose |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | Placebo Comparator |
| donepezil | DRUG | Active Comparator |
| ABT-126 | DRUG | low dose, middle dose, high dose |
Inclusion Criteria: * The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject. * The sub...